BioSpace News Archive

Bausch Health Companies Inc. announced it has paid down an additional $100 million of its senior secured term loans using cash generated from operations.

Illumina, Inc. announced its financial results for the fourth quarter and fiscal year 2018.

Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3) additional lots of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, to the retail (pharmacy) level.

Select Medical Holdings Corporation, will release the financial results for its fourth quarter and full year ended December 31, 2018 on Thursday, February 21, 2019 after the market closes.

BIOASIS TECHNOLOGIES INC. announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Nov. 30, 2018.

Merck, known as MSD outside the United States and Canada, announced that Mary Ellen Coe, president, Google Customer Solutions, at Google Inc. will join the company’s Board of Directors effective March 18, 2019.

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, will participate in the 8th Annual SVB Leerink Global Healthcare Conference at the Lotte New York Palace in New York, New York.

Baxter International, Inc., a leading global medical products company, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York, NY on Thursday, February 28, 2019.

Research that demonstrates how Bio-Rad’s Droplet Digital PCR (ddPCR) technology can quickly help determine the effectiveness of immune checkpoint inhibitors and other immunotherapies will be presented by cancer researchers and medical oncologists during a Bio-Rad workshop at the Precision Medicine World Conference (PMWC) in Santa Clara, California, January 20–23.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR), today announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined.